Author + information
- Angkawipa Trongtorsak,
- Kitravee Kongnatthasate,
- Paweena Susantitaphong,
- Veraprapas Kittipibul and
- Aekarach Ariyachaipanich
Background: Coenzyme Q10 (CoQ10) has a crucial role in energy production, and is found to be reduced in patients with heart failure (HF); however, the effect of CoQ10 on left ventricular remodeling is unknown. The aim of this study was to evaluate the left ventricular parameters and clinical outcomes in patients with HF using a meta-analysis from randomized studies.
Methods: We searched on PubMed, Embase, Cochrane Library databases and relevant references from 1978 to April 2016 to identify randomized control trials that investigate the CoQ10 in patients with HF. Relevant articles were selected by two independent reviewers. We assessed the mean difference of CoQ10 level, left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD). Weighted mean difference was calculated using either fixed- or random-effects models based on the heterogeneity of the studies. The hazard ratio for all-cause death and hospitalization were calculated.
Results: Of 375 identified articles, 16 studies with total of 1,662 individuals met eligibility criteria for review. These studies were consisting of 9 parallel and 7 crossover studies. With CoQ10 supplement, the plasma Q10 level was significantly higher (mean difference of 1.44 mcg/dL, 95% confidence interval (CI) 1.16 – 1.73 mcg/dL, p < 0.001), the LVEF and LVESD were significantly improved by 2.9% (95% CI 1.3 – 4.5%, p = 0.001) and 2.1 mm (95% CI 3.5 – 0.6 mm, p = 0.006), respectively but not the LVEDD (1.0 mm, 95% CI 3.74 to −1.82, P = 0.50). For the endpoint of all-cause death, the pooled hazard ratio was 0.62 (95% CI 0.40-0.95, p = 0.03). Adding CoQ10 compared with placebo was associated with less hospitalization (hazard ratio = 0.39 95% CI 0.29 – 0.53, p<0.001).
Conclusions: This meta-analysis supports use of combined CoQ10 with standard therapy in HF to reduce mortality. The benefit may partially explained by reversed remodeling of the left ventricle.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1121-249
- 2017 American College of Cardiology Foundation